Telix Pharmaceuticals Limited (TLX) generates a steady flow of news related to its radiopharmaceutical pipeline, commercial portfolio, and global operations. As a biopharmaceutical company focused on therapeutic and diagnostic radiopharmaceuticals and associated medical technologies, its announcements often highlight progress in oncology and rare disease programs, regulatory milestones, and commercial performance.
Recent Telix news has covered precision medicine portfolio updates, including Phase 3 data for TLX591-CDx (Illuccix) in China, regulatory interactions for TLX101-CDx (Pixclara) and TLX250-CDx (Zircaix) with the U.S. Food and Drug Administration, and inclusion of TLX250-CDx in international renal imaging guidelines. The company also reports on clinical collaborations, such as its agreement with Varian to explore combining Telix’s theranostic products with external beam radiation therapy.
Investors and clinicians following TLX news can expect updates on clinical trial milestones (for example, first patient dosed in the SOLACE trial for TLX090 or in the BiPASS Phase 3 trial for prostate cancer diagnosis), as well as information on reimbursement and market access developments. Telix has announced CMS Transitional Pass-Through status and a permanent HCPCS code for Gozellix in the United States, along with country-level approvals and launches for Illuccix in Europe and the United Kingdom.
Telix also issues news on financial performance and guidance, such as quarterly revenue updates and full-year revenue outlook, and on participation in major healthcare conferences where management presents the company’s pipeline and commercial strategy. For users tracking TLX, the news stream provides insight into how Telix advances its radiopharmaceutical products from clinical development through regulatory review and commercialization across multiple regions.
Telix Pharmaceuticals (ASX/NASDAQ: TLX) reported Q2 2026 group revenue of US$247 million, up 7% QoQ and 21% YoY. Precision Medicine revenue reached US$202 million, up 9% QoQ and 30% YoY, while Telix Manufacturing Solutions delivered US$45 million, down 6% YoY.
Telix expects FY 2026 revenue and other income to exceed US$1 billion, with revenue tracking near the upper end of its US$950–970 million guidance plus US$40 million non-refundable income from a new Regeneron strategic collaboration. R&D spend guidance was increased to US$230–270 million.
The quarter featured FDA alignment to advance Part 2 of the ProstACT Global Phase 3 trial of TLX591-Tx in the U.S., pivotal and Phase 2 trial progress for TLX597-Tx, TLX250-Tx and TLX101-Tx, rapid enrollment in the BiPASS™ Phase 3 prostate imaging study, and key regulatory steps for Pixclara®, Pixlumi® and Zircaix®.
Telix expanded its global manufacturing network with milestones in North Melbourne, Brussels and Yokohama, entered a multi-program radiopharmaceutical collaboration with Regeneron, refinanced its convertible bonds by issuing US$600 million due 2031 and repurchasing 2029 notes, and appointed three new Non-Executive Directors.
Telix (ASX: TLX, NASDAQ: TLX) has dosed the first patient in the Phase 3 LUTEON trial of TLX250-Tx (lutetium-177 girentuximab tetraxetan) for relapsed or recurrent clear cell renal cell carcinoma (ccRCC). LUTEON is a randomized, prospective, open-label, multi-center study and is described as the first Phase 3 radiopharmaceutical therapy trial in ccRCC targeting carbonic anhydrase IX (CAIX).
The first patient was treated at GenesisCare Murdoch in Western Australia under Principal Investigator Dr. Aviral Singh. TLX250-Tx is a first-in-class CAIX-targeting radio antibody-drug conjugate designed to deliver lutetium-177 directly to CAIX-positive tumors, which Telix notes are present in more than 95% of ccRCC cases while showing limited expression in normal tissues. The LUTEON program is part of Telix’s global development strategy and uses the investigational PET imaging agent TLX250-Px (Zircaix) to identify CAIX-positive patients.
Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) and St Vincent’s Hospital Sydney reported that the first patients have been dosed with TLX597-Tx in the Phase 2 OPTIMAL-e trial for men with metastatic hormone-sensitive prostate cancer (mHSPC). The single-arm, open-label study at St Vincent’s evaluates adaptive-dosed TLX597-Tx, a next-generation PSMA-targeting radioligand therapy, in combination with androgen deprivation therapy and an androgen receptor pathway inhibitor.
The trial will measure prostate-specific antigen (PSA) response rate, depth and durability of response, and further assess safety of dose intensification in an earlier treatment setting. According to Telix, prior OPTIMAL-PSMA studies showed favorable biodistribution and dosimetry with low exposure to salivary glands and kidneys and high uptake in PSMA-expressing tumors. TLX597-Tx has not received marketing authorization in any jurisdiction.
Telix (ASX: TLX, NASDAQ: TLX) reported that the U.S. FDA has agreed that Part 1 safety data from the ProstACT Global Phase 3 trial support advancing Part 2 in the United States.
The FDA aligned with Telix on the Part 2 protocol, statistical analysis, and safety monitoring for TLX591-Tx given in two doses, 14 days apart, combined with abiraterone, enzalutamide, or docetaxel. Part 2 continues enrolling where already approved, while U.S. initiation awaits review of an IND amendment, coordinated with a pending European submission.
Telix (TLX) will host an educational webinar on neurologic oncology, focusing on glioma, glioblastoma and theranostic approaches. Group Chief Medical Officer Dr David N. Cade will give a clinical update, followed by a fireside chat with leading European neuro-oncology and nuclear medicine specialists.
The webinar includes a Q&A with Dr Cade and Telix Therapeutics CEO Richard Valeix. It is scheduled for June 29, 2026, 5:00 p.m. EDT / June 30, 2026, 7:00 a.m. AEST, with online registration required.
Telix (TLX) and United Imaging signed a U.S. Memorandum of Understanding for a strategic research collaboration in integrated theranostics.
The partners plan to combine Telix’s molecular imaging products with United Imaging’s scanner, software, connectivity and AI platforms, initially focusing on TLX101-Px (Pixclara, Floretyrosine F 18) in the U.S.
Telix (ASX:TLX, NASDAQ:TLX) reported Part 1 results from the global Phase 3 ProstACT trial of TLX591-Tx in post-ARPI metastatic castration-resistant prostate cancer, presented as a late-breaking oral at ASCO 2026.
Across 36 patients given TLX591-Tx plus standard of care, safety and tolerability were acceptable with no new safety signals. Radiation doses to key organs were below established limits, pharmacokinetics showed sustained tumor activity at Day 15, and Part 2 randomized expansion is underway where approved, with FDA engagement ongoing.
Telix (ASX:TLX, NASDAQ:TLX) announced that Managing Director and Group CEO Dr. Christian Behrenbruch will present at the William Blair 46th Annual Growth Stock Conference in Chicago on June 2, 2026, and the Jefferies Global Healthcare Conference in New York on June 3, 2026. Both sessions will be available via live webcast on Telix’s investor relations website.
Telix Pharmaceuticals (ASX:TLX, NASDAQ:TLX) reported completion of patient enrolment in the Phase 1 IPAX-2 dose-finding study of TLX101-Tx in newly diagnosed glioblastoma. Twelve patients across four sites received up to two 5GBq doses (10GBq total) with no dose-limiting toxicities observed.
IPAX-2 will confirm the maximum tolerated dose alongside standard-of-care therapy, while pivotal Phase 3 trial IPAX BrIGHT in recurrent glioblastoma is actively enrolling, described as the first radiopharmaceutical therapy to reach Phase 3 for this cancer.
Telix (ASX/NASDAQ: TLX) announced letters of intent to collaborate with EDAP and Profound Medical to explore investigational use of its PSMA-PET imaging agents Gozellix and Illuccix with minimally invasive, image-guided ablative therapies for localized prostate cancer, including robotic HIFU and MRI-guided TULSA.
Initial work will focus on patient selection, treatment planning, post-treatment monitoring and clinical evidence generation to inform best practices and support emerging workflows aiming to preserve healthy tissue and reduce side effects.